UBS initiated coverage on Zimmer Biomet with a new price target
UBS initiated coverage of Zimmer Biomet with a rating of Buy and set a new price target of $115.00
- UBS initiated coverage on TransMedics Group with a new price target
UBS initiated coverage of TransMedics Group with a rating of Neutral and set a new price target of $80.00
- UBS initiated coverage on Teleflex with a new price target
UBS initiated coverage of Teleflex with a rating of Neutral and set a new price target of $145.00
- UBS initiated coverage on Steris with a new price target
UBS initiated coverage of Steris with a rating of Buy and set a new price target of $275.00
- Visteon downgraded by Wolfe Research
Wolfe Research downgraded Visteon from Outperform to Peer Perform
- Spyre Therapeutics downgraded by Wolfe Research
Wolfe Research downgraded Spyre Therapeutics from Outperform to Peer Perform
- Honeywell upgraded by BofA Securities with a new price target
BofA Securities upgraded Honeywell from Underperform to Neutral and set a new price target of $265.00
- Grupo Cibest S.A. upgraded by Goldman with a new price target
Goldman upgraded Grupo Cibest S.A. from Neutral to Buy and set a new price target of $98.00
- Gossamer Bio upgraded by Leerink Partners with a new price target
Leerink Partners upgraded Gossamer Bio from Market Perform to Outperform and set a new price target of $1.00
- UBS initiated coverage on SI-BONE with a new price target
UBS initiated coverage of SI-BONE with a rating of Buy and set a new price target of $24.00
- Solventum upgraded by UBS with a new price target
UBS upgraded Solventum from Neutral to Buy and set a new price target of $95.00
- UBS initiated coverage on Shoulder Innovations with a new price target
UBS initiated coverage of Shoulder Innovations with a rating of Buy and set a new price target of $27.00
- William Blair initiated coverage on Rapport Therapeutics
William Blair initiated coverage of Rapport Therapeutics with a rating of Outperform
- PROCEPT BioRobotics downgraded by UBS with a new price target
UBS downgraded PROCEPT BioRobotics from Buy to Neutral and set a new price target of $20.00
- MapLight Therapeutics downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded MapLight Therapeutics from Overweight to Equal-Weight and set a new price target of $21.00
- Medtronic upgraded by UBS with a new price target
UBS upgraded Medtronic from Neutral to Buy and set a new price target of $100.00
- UBS initiated coverage on Intuitive Surgical with a new price target
UBS initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $500.00
- UBS initiated coverage on Integra with a new price target
UBS initiated coverage of Integra with a rating of Neutral and set a new price target of $19.00
- Wells Fargo initiated coverage on GXO Logistics with a new price target
Wells Fargo initiated coverage of GXO Logistics with a rating of Overweight and set a new price target of $18.00
- UBS initiated coverage on Glaukos
UBS initiated coverage of Glaukos with a rating of Neutral